MV BioTherapeutics SA

Swiss Biotech Association

Member

A Swiss microbiota biotherapeutics and mucosal vaccines company with two technology platforms: ApyraVax for the generation of innovative mucosal vaccines; ApyraMed with indication as enhancer in cancer immunotherapy and corrector of dysbiosis induced by antibiotic treatments and unhealthy diet.

https://www.mv-bio.com/
+41 58 666 72 25
fgrassi@mv-bio.com
Fabio Grassi

Location

Via Francesco Chiesa 5, 6500 Bellinzona, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2018
Number of employees in Switzerland

1-9

Key business

Core competencies

You may also be interested in

Trialize AG

Revolutionizing clinical trials, Trialize's cutting-edge automation platform accelerates study build times by 4x and curbs manual labor by up to 73%, enhancing data quality, patient adherence, and team morale. It's a game-changer in modern, decentralized, and virtual studies.
6300 Zug

Member

CELLnTEC Advanced Cell Systems

CELLnTEC technologies enable science and industry to develop innovations in stem cell research, regenerative medicine, cell-based therapies, and beyond. The company is a pioneering developer of chemically defined, animal and human components-free precision media.
3014 Bern

Member

Caland SA

Caland SA provides a professional, confidential, competitive and impeccable service of pharma-grade CO2 extraction, distillation and cannabis formulation based on GMP requirements.
A modern production line, coupled to a qualified ERP, ensures uncompromising quality of all products and services.
2800 Delémont

Member